Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term.

On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. He noted that the Data Monitoring Committee also suggested expanding registration in Cobenfy’s ADEPT-2 trial in Alzheimer’s disease psychosis patients.

Bristol-Myers Squibb Company (NYSE:BMY) has been encountering some difficulties over the past few years due to patent cliffs. However, the company has a lot of products in the pipeline, especially in the oncology market. In the third quarter of 2025, BMY’s growth portfolio revenue grew by 18% to $6.9 billion, mainly driven by its immuno-oncology portfolio. Its total revenues for the quarter came in at $12.2 billion, up 3% from the same period last year.

Though Bristol-Myers Squibb Company (NYSE:BMY)’s outlook is very promising, the company might be struggling on the dividend front. Is payout ratio is around 80%, which isn’t encouraging news for income investors. However, the company’s trailing twelve-month free cash flow of $15.3 billion was sufficient to cover dividend payments worth $5 billion. BMY has also raised its payouts for 16 consecutive years.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that discovers and manufactures medicines and treatments for serious illnesses.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.